Showing 8621-8630 of 20878 results for "".
In-Office Drug Testing for Retinal Conditions
https://reachmd.com/programs/revealing-retina/in-office-drug-testing-for-retinal-conditions/5138/What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabeticGLP-1 Use and AMD Risk
https://reachmd.com/clinical-practice/ophthalmology/glp-1-use-and-amd-risk/48970/Could GLP-1s originally designed for diabetes and weight loss influence the risk of developing wet AMD? In this episode of New Retina Radio Journal Club with VBS, host Barton Blackorby, MD, is joined by Katharine Talcott, MD, and Hong-Uyen Hua, MD, to discuss a large national cohort study examiningSoccer Injuries and How to Treat Them
https://reachmd.com/programs/focus-on-sports-medicine/soccer-injuries-and-how-to-treat-them/3670/The sports hernia is one of the most difficult injuries to diagnose and treat in elite soccer players. Join host Dr. Sherwin Ho as he talks with Dr. Riley Williams, associate professor of orthopedic surgery at Weill Medical College and medical director for the New York Red Bulls professional soccerTreating Brain Tumors with Immunotherapy
https://reachmd.com/programs/advanced-treatments-innovations-mayo-clinic/treating-brain-tumors-with-immunotherapy/12028/With brain cancer presenting its own unique set of challenges, how can we be sure that immunotherapy is the right treatment option?Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
https://reachmd.com/programs/cme/enhancing-collaborative-care-in-retinal-diseases-a-focus-on-injection-therapies/37715/Explore strategies to improve retinal disease referrals and adherence to anti-VEGF therapy through interdisciplinary collaboration.Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
https://reachmd.com/programs/cme/secondary-stroke-prevention-emerging-role-factor-xi-inhibition/50969/Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn’t have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You’ll break doRedefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
https://reachmd.com/programs/cme/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/How are SC immune checkpoint inhibitors changing care in solid tumors? Hear a physician–nurse interview and explore implications for your practice.Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
https://reachmd.com/programs/cme/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
https://reachmd.com/programs/cme/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Real-World Impact of Evolocumab on MACE Reduction in ASCVD
https://reachmd.com/clinical-practice/cardiology/real-world-impact-of-evolocumab-on-mace-reduction-in-ascvd/39991/Review real-world data on evolocumab and its association with reduced MACE in patients with established atherosclerotic cardiovascular disease.